Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- Home

Lipids and lipoproteins

14 findings across 9 drug records. Domain pages are descriptive indexes, not advice.

Most represented records

Retatrutide (3)

Pemvidutide (2)

Survodutide (2)

Tirzepatide (2)

Dulaglutide (1)

Evidence spread

High evidence 0 Moderate evidence 9 Low evidence 4 Very low evidence 1

Dulaglutide MARKETED
Lipids and lipoproteins Decrease
Low evidence

In a small uncontrolled interventional pilot in adults with type 2 diabetes and verified atherosclerosis, dulaglutide treatment was followed by a significant reduction...

Hachula M, Kosowski M, Basiak M, Okopien B, Medicina (Kaunas) 2024;60(6):908 Source
Full findingIn a small uncontrolled interventional pilot in adults with type 2 diabetes and verified atherosclerosis, dulaglutide treatment was followed by a significant reduction in lipoprotein(a) [Lp(a)] and in the plaque-instability markers pentraxin-3 and MMP-9, while the conventional lipid fractions (LDL-C, triglycerides, non-HDL-C, HDL-C) did NOT change significantly.
PopulationUncontrolled single-arm interventional pilot (pre/post, no comparator, not randomised); N=34 adults (age 41-81, median 61) with type 2 diabetes, dyslipidaemia (88% on statins) and ultrasound-verified carotid atherosclerosis; dulaglutide 1.5-3 mg, 180 days.
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitssmall sample (N~34)
Orforglipron INVESTIGATIONAL
Lipids and lipoproteins Decrease
Moderate evidence

Orforglipron significantly lowered LDL-C, TG, ApoB and ApoC3 versus placebo in phase 2 (plateau at >=12 mg).

Wharton S et al., Cardiovasc Diabetol, 2025;24(1):240 Source
PopulationPhase 2 pooled: T2D N=361 (26 wk), obesity N=234 (36 wk); orforglipron 3-45 mg vs placebo (+dulaglutide in T2D).
Fundingindustry - Eli Lilly and Company
Scope limitssurrogate/exploratory endpoint
Comparatorsplacebo; dulaglutide 1.5 mg (T2D study)
Pemvidutide INVESTIGATIONAL
Lipids and lipoproteins Decrease
Low evidence

Pemvidutide produced large TG and LDL/total-cholesterol reductions in phase 2 MOMENTUM obesity (glucagon-driven lipid effect).

Altimmune MOMENTUM Phase 2 (ADA 2024, abstract 262-OR) Source
PopulationPhase 2 MOMENTUM; overweight/obesity; pemvidutide 1.2/1.8/2.4 mg vs placebo; 48 weeks.
Fundingindustry - Altimmune (sponsor of record; disclosed)
Scope limitsconference/abstract-level; identifier not fully verified
Comparatorsplacebo
Retatrutide INVESTIGATIONAL
Lipids and lipoproteins Decrease
Moderate evidence

Retatrutide produced strong dose-dependent triglyceride and LDL lowering in phase 2 obesity (glucagon-agonism-enhanced lipid effect).

Jastreboff AM et al. (retatrutide phase 2), NEJM, 2023;389:514-526 Source
PopulationN=338 adults with obesity; retatrutide 1-12 mg vs placebo; 48 weeks; phase 2 (NCT04881760).
Fundingindustry-Eli Lilly
Scope limitsconference/abstract-level; magnitude web/secondary-sourced; surrogate/exploratory endpoint
Comparatorsplacebo
Retatrutide INVESTIGATIONAL
Lipids and lipoproteins Decrease
Moderate evidence

In post-hoc analyses of two phase-2 retatrutide trials, circulating ANGPTL3/8 complex concentrations fell dose-dependently and these decreases paralleled the...

Wen Y, Lemen D, ... Konrad RJ, Diabetes Obes Metab 2025;27(10):5985-5995 Source
Full findingIn post-hoc analyses of two phase-2 retatrutide trials, circulating ANGPTL3/8 complex concentrations fell dose-dependently and these decreases paralleled the retatrutide-induced reductions in triglycerides and LDL-C.
PopulationPost-hoc analysis of two phase-2 retatrutide RCTs: participants with type 2 diabetes and participants with obesity/overweight without diabetes; ANGPTL3/8 measured by dedicated immunoassay from baseline.
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Scope limitspost-hoc (not prespecified)
Comparatorsplacebo
Retatrutide INVESTIGATIONAL
Lipids and lipoproteins Decrease
Moderate evidence

In the phase-2a MASLD substudy, retatrutide was associated with a significant reduction in fasting triglycerides (and improved insulin-sensitivity markers); the paper...

Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-as... Source
Full findingIn the phase-2a MASLD substudy, retatrutide was associated with a significant reduction in fasting triglycerides (and improved insulin-sensitivity markers); the paper additionally cites improvements in non-HDL cholesterol from other retatrutide trials in people with type 2 diabetes or obesity.
PopulationPhase-2a MASLD substudy of the retatrutide obesity phase-2 trial (NCT04881760); N=98 adults with obesity and MASLD (>=10% liver fat); retatrutide 1-12 mg vs placebo; 48 weeks.
Fundingindustry-Eli Lilly
Scope limitssmall sample (N~98); prespecified/exploratory secondary of RCT (substudy)
Comparatorsplacebo
Semaglutide MARKETED
Lipids and lipoproteins Decrease
Low evidence

Semaglutide 2.4 mg improved the lipid profile (TG, total/LDL cholesterol) versus placebo across the STEP programme.

Amaro A et al. (STEP cardiometabolic review), Postgrad Med, 2022;134(sup1):18-27 Source
PopulationAdults with overweight/obesity, STEP 1-5; 68 weeks; RCT.
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsReview summary; semaglutide lipid effects generally milder than glucagon co-agonists (no direct glucagon-driven hepatic TG effect). PMID/DOI verified.
Comparatorsplacebo
Survodutide INVESTIGATIONAL
Lipids and lipoproteins Decrease
Low evidence

Survodutide reduced TG, total and LDL cholesterol and VLDL in phase 2 obesity; HDL relatively unchanged.

Survodutide phase 2 cardiometabolic, Eur Heart J, 2024;45(Suppl 1):ehae666.2895 Source
PopulationN=387 adults BMI >=27 without diabetes; survodutide 0.6-4.8 mg vs placebo; 46 weeks; phase 2.
Fundingindustry - Boehringer Ingelheim / Zealand (trial sponsor; inferred from registration trial)
Scope limitsconference/abstract-level
Comparatorsplacebo
Tirzepatide MARKETED
Lipids and lipoproteins Decrease
Moderate evidence

Tirzepatide dose-dependently improves the atherogenic lipoprotein profile: lowers TG, VLDL-C, ApoB, ApoC-III and small LDL particles; ApoC-III reduction partly...

Wilson JM et al., Diabetes Obes Metab, 2020;22(12):2451-2459 Source
Full findingTirzepatide dose-dependently improves the atherogenic lipoprotein profile: lowers TG, VLDL-C, ApoB, ApoC-III and small LDL particles; ApoC-III reduction partly weight-independent.
PopulationPhase 2b T2D substudy (tirzepatide 1-15 mg vs dulaglutide vs placebo); NMR lipoprotein analysis.
Fundingindustry - Eli Lilly (trial sponsor)
Scope limitsKey mechanistic ApoC-III finding. SURPASS-2 head-to-head vs semaglutide also reported larger TG/lipid improvements with tirzepatide (not separately captured). PMID/DOI verified.
Comparatorsdulaglutide; placebo
Tirzepatide MARKETED
Lipids and lipoproteins Decrease
Moderate evidence

In a post-hoc analysis of the phase-3 SURMOUNT-1 obesity trial, tirzepatide-associated improvements in triglycerides, HDL-C, LDL-C and non-HDL cholesterol were...

Linetzky B, Sattar N, Verma S, Krumholz HM, et al., Ann Intern Med 2025;178(8):1095-1105 Source
Full findingIn a post-hoc analysis of the phase-3 SURMOUNT-1 obesity trial, tirzepatide-associated improvements in triglycerides, HDL-C, LDL-C and non-HDL cholesterol were primarily observed only after weight reductions greater than 10%.
PopulationPost-hoc analysis of phase-3 double-blind SURMOUNT-1 (NCT04184622); N=1605 adults with obesity or overweight-with-complications without diabetes; tirzepatide 5/10/15 mg; baseline to week 72.
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Scope limitspost-hoc (not prespecified)
Comparatorsplacebo
Cotadutide MARKETED
Lipids and lipoproteins Decrease
Moderate evidence

Improvements in lipid profile with cotadutide 300 µg vs placebo

Nahra R et al. Diabetes Care 2021;44:1433-1442 Source
PopulationOverweight/obese T2D, phase 2b (n=834), 54 wk, RCT
Fundingindustry-AstraZeneca
Scope limitsconference/abstract-level; identifier not fully verified; open-label (unblinded)
Comparatorsplacebo; liraglutide 1.8 mg
Mazdutide INVESTIGATIONAL
Lipids and lipoproteins Decrease
Moderate evidence

Reduced total cholesterol, triglycerides, LDL-C and serum uric acid

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source
PopulationChinese overweight/obese (n=610), phase 3, 48 wk
FundingInnovent Biologics
Scope limitsMagnitude unconfirmed Magnitude press-derived (re-pointed 2026-06-23 from the duplicate press/registry GLORY-1 row to the genuine published source PMID40421736; figures pending full-text confirmation).
Comparatorsplacebo
Pemvidutide INVESTIGATIONAL
Lipids and lipoproteins Decrease
Very low evidence

Robust reductions in serum lipids

Altimmune MOMENTUM topline / ADA 2024 Source
PopulationMOMENTUM obesity phase 2 (n=391), 48 wk
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Scope limitsconference/abstract-level; identifier not fully verified; no outcome data yet (ongoing); small sample (N~50)
Comparatorsplacebo
Survodutide INVESTIGATIONAL
Lipids and lipoproteins Mixed
Moderate evidence

Reductions in total cholesterol, LDL-C, triglycerides; increase in HDL-C

le Roux CW et al. Lancet Diabetes Endocrinol 2024;12:162-173 Source
PopulationAdults with obesity, phase 2 (n=387), 46 wk
Fundingindustry-Boehringer Ingelheim
Scope limitsidentifier not fully verified
Comparatorsplacebo